PMID- 36618937
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230111
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Liver-related long-term outcomes of alpha-glucosidase inhibitors in patients with 
      diabetes and liver cirrhosis.
PG  - 1049094
LID - 10.3389/fphar.2022.1049094 [doi]
LID - 1049094
AB  - Background: Adequate management of diabetes in patients with liver cirrhosis can 
      be challenging. We conducted this study to investigate the liver-related long 
      term outcomes of alpha-glucosidase inhibitors (AGIs) in patients with diabetes 
      and cirrhosis. Methods: From National Health Insurance Research Database (NHIRD) 
      in Taiwan, we recruited propensity-score matched alpha-glucosidase inhibitor 
      users and non-users from a cohort of type 2 diabetes mellitus (T2DM) with 
      compensated liver cirrhosis between 1 January 2000, and 31 December 2017, and 
      followed them until 31 December 2018. Cox proportional hazards models with robust 
      sandwich standard error estimates were used to assess the risk of main outcomes 
      for alpha-glucosidase inhibitor users versus non-users. Results: The incidence 
      rates of mortality during follow-up were 65.56 vs. 96.06 per 1,000 patient-years 
      for alpha-glucosidase inhibitor users and non-users, respectively. The 
      multivariable-adjusted model shows that alpha-glucosidase inhibitor users had 
      significantly lower risks of all-cause mortality (aHR 0.63, 95% CI 0.56-0.71), 
      hepatocellular carcinoma (aHR 0.55, 95% CI 0.46-0.67), decompensated cirrhosis 
      (aHR 0.74 95% CI 0.63-0.87), hepatic encephalopathy (aHR 0.72, 95% CI 0.60-0.87), 
      and hepatic failure (aHR 0.74, 95% CI 0.62-0.88) than alpha-glucosidase inhibitor 
      non-users. Patients who received alpha-glucosidase inhibitors for a cumulative 
      duration of more than 364 days had significantly lower risks of these outcomes 
      than non-users. Conclusion: Alpha-glucosidase inhibitor use was associated with a 
      lower risk of mortality, hepatocellular carcinoma, decompensated cirrhosis, and 
      hepatic failure in patients with diabetes and compensated cirrhosis. 
      alpha-glucosidase inhibitors may be useful for the management of diabetes in 
      patients with compensated liver cirrhosis. Large-scale prospective studies are 
      required to verify our results.
CI  - Copyright (c) 2022 Yen, Hou, Wei, Shih, Hsu, Hsu and Hwu.
FAU - Yen, Fu-Shun
AU  - Yen FS
AD  - Yen's Clinic, Taoyuan, Taiwan.
FAU - Hou, Ming-Chih
AU  - Hou MC
AD  - Division of Gastroenterology and Hepatology, Department of Medicine, Taipei 
      Veterans General Hospital, Taipei, Taiwan.
AD  - Institute of Clinical Medicine, School of Medicine, National Yang-Ming Chiao Tung 
      University, Taipei, Taiwan.
FAU - Wei, James Cheng-Chung
AU  - Wei JC
AD  - Department of Allergy, Immunology and Rheumatology, Chung Shan Medical University 
      Hospital, Taichung, Taiwan.
AD  - Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
AD  - Graduate Institute of Integrated Medicine, China Medical University, Taichung, 
      Taiwan.
FAU - Shih, Ying-Hsiu
AU  - Shih YH
AD  - Management Office for Health Data, China Medical University Hospital, Taichung, 
      Taiwan.
AD  - College of Medicine, China Medical University, Taichung, Taiwan.
FAU - Hsu, Chung Y
AU  - Hsu CY
AD  - Graduate Institute of Biomedical Sciences, China Medical University, Taichung, 
      Taiwan.
FAU - Hsu, Chih-Cheng
AU  - Hsu CC
AD  - Institute of Population Health Sciences, National Health Research Institutes, 
      Taipei, Miaoli, Taiwan.
AD  - Department of Health Services Administration, China Medical University, Taichung, 
      Taiwan.
AD  - Department of Family Medicine, Min-Sheng General Hospital, Taoyuan, Taiwan.
AD  - National Center for Geriatrics and Welfare Research, National Health Research 
      Institutes, Taipei, Miaoli, Taiwan.
FAU - Hwu, Chii-Min
AU  - Hwu CM
AD  - Institute of Clinical Medicine, School of Medicine, National Yang-Ming Chiao Tung 
      University, Taipei, Taiwan.
AD  - Section of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans 
      General Hospital, Taipei, Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20221221
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9812564
OTO - NOTNLM
OT  - all-cause mortality
OT  - decompensated cirrhosis
OT  - hepatic encephalopathy
OT  - hepatic failure
OT  - hepatocellular carcinoma
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/01/10 06:00
MHDA- 2023/01/10 06:01
PMCR- 2022/12/21
CRDT- 2023/01/09 03:41
PHST- 2022/09/20 00:00 [received]
PHST- 2022/12/12 00:00 [accepted]
PHST- 2023/01/09 03:41 [entrez]
PHST- 2023/01/10 06:00 [pubmed]
PHST- 2023/01/10 06:01 [medline]
PHST- 2022/12/21 00:00 [pmc-release]
AID - 1049094 [pii]
AID - 10.3389/fphar.2022.1049094 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Dec 21;13:1049094. doi: 10.3389/fphar.2022.1049094. 
      eCollection 2022.